Rockwell Medical Q1 net loss $7.2M, DaVita invests $7.5M and amends supply deal

ROCKWELL MEDICAL, INC.

2022-Q1 EPS reported -$0.84 revenue$16,124,000

Q1 net sales $16.1M (+4.2% YoY); gross loss $0.8M vs. gross profit $0.4M last year due to inflation.
Net loss $7.2M ($0.84/sh) compared to $7.8M ($0.91/sh) in Q1 2021; cash $9.9M at March 31.
DaVita amended supply agreement with price increases and cost pass-through; invested $7.5M in convertible preferred stock, with potential additional $7.5M.
Submitted supplemental data to FDA for IND to enable Phase 2 FPC home infusion trial; awaiting 30-day review.
Partner Wanbang completed Phase 3 Triferic Dialysate enrollment in China; NDA submission targeted Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKWELL MEDICAL, INC. reported three months ended March 31, 2022 results: revenue $16.1 million.

Period: three months ended March 31, 2022
Revenue: $16.1 million
Result: reported results

Exact text from the filing

Revenues were $16.1 million for the three months ended March 31, 2022, compared to $15.5 million for the three months ended March 31, 2021.

View on SEC.gov

Browse all earnings releases →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001628280-22-014491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.